The Melding of Drug Screening Platforms for Melanoma
The global incidence of cancer is rising rapidly and continues to be one of the leading causes of death in the world. Melanoma deserves special attention since it represents one of the fastest growing types of cancer, with advanced metastatic forms presenting high mortality rates due to the developm...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00512/full |
| _version_ | 1819055827030376448 |
|---|---|
| author | Gabriela Klein Couto Natália Vieira Segatto Thaís Larré Oliveira Fabiana Kömmling Seixas Kyle M. Schachtschneider Kyle M. Schachtschneider Kyle M. Schachtschneider Tiago Collares |
| author_facet | Gabriela Klein Couto Natália Vieira Segatto Thaís Larré Oliveira Fabiana Kömmling Seixas Kyle M. Schachtschneider Kyle M. Schachtschneider Kyle M. Schachtschneider Tiago Collares |
| author_sort | Gabriela Klein Couto |
| collection | DOAJ |
| description | The global incidence of cancer is rising rapidly and continues to be one of the leading causes of death in the world. Melanoma deserves special attention since it represents one of the fastest growing types of cancer, with advanced metastatic forms presenting high mortality rates due to the development of drug resistance. The aim of this review is to evaluate how the screening of drugs and compounds for melanoma has been performed over the last seven decades. Thus, we performed literature searches to identify melanoma drug screening methods commonly used by research groups during this timeframe. In vitro and in vivo tests are essential for the development of new drugs; however, incorporation of in silico analyses increases the possibility of finding more suitable candidates for subsequent tests. In silico techniques, such as molecular docking, represent an important and necessary first step in the screening process. However, these techniques have not been widely used by research groups to date. Our research has shown that the vast majority of research groups still perform in vitro and in vivo tests, with emphasis on the use of in vitro enzymatic tests on melanoma cell lines such as SKMEL and in vivo tests using the B16 mouse model. We believe that the union of these three approaches (in silico, in vitro, and in vivo) is essential for improving the discovery and development of new molecules with potential antimelanoma action. This workflow would provide greater confidence and safety for preclinical trials, which will translate to more successful clinical trials and improve the translatability of new melanoma treatments into clinical practice while minimizing the unnecessary use of laboratory animals under the principles of the 3R's. |
| first_indexed | 2024-12-21T13:13:42Z |
| format | Article |
| id | doaj.art-e6832dc548d546d89fbd0a17e77012e6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T13:13:42Z |
| publishDate | 2019-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e6832dc548d546d89fbd0a17e77012e62022-12-21T19:02:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-06-01910.3389/fonc.2019.00512456984The Melding of Drug Screening Platforms for MelanomaGabriela Klein Couto0Natália Vieira Segatto1Thaís Larré Oliveira2Fabiana Kömmling Seixas3Kyle M. Schachtschneider4Kyle M. Schachtschneider5Kyle M. Schachtschneider6Tiago Collares7Research Group in Molecular and Cellular Oncology, Postgraduate Program in Biochemistry and Bioprospecting, Cancer Biotechnology Laboratory, Center for Technological Development, Federal University of Pelotas, Pelotas, BrazilBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilDepartment of Radiology, University of Illinois at Chicago, Chicago, IL, United StatesDepartment of Biochemistry & Molecular Genetics, University of Illinois at Chicago, Chicago, IL, United StatesNational Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, IL, United StatesBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilThe global incidence of cancer is rising rapidly and continues to be one of the leading causes of death in the world. Melanoma deserves special attention since it represents one of the fastest growing types of cancer, with advanced metastatic forms presenting high mortality rates due to the development of drug resistance. The aim of this review is to evaluate how the screening of drugs and compounds for melanoma has been performed over the last seven decades. Thus, we performed literature searches to identify melanoma drug screening methods commonly used by research groups during this timeframe. In vitro and in vivo tests are essential for the development of new drugs; however, incorporation of in silico analyses increases the possibility of finding more suitable candidates for subsequent tests. In silico techniques, such as molecular docking, represent an important and necessary first step in the screening process. However, these techniques have not been widely used by research groups to date. Our research has shown that the vast majority of research groups still perform in vitro and in vivo tests, with emphasis on the use of in vitro enzymatic tests on melanoma cell lines such as SKMEL and in vivo tests using the B16 mouse model. We believe that the union of these three approaches (in silico, in vitro, and in vivo) is essential for improving the discovery and development of new molecules with potential antimelanoma action. This workflow would provide greater confidence and safety for preclinical trials, which will translate to more successful clinical trials and improve the translatability of new melanoma treatments into clinical practice while minimizing the unnecessary use of laboratory animals under the principles of the 3R's.https://www.frontiersin.org/article/10.3389/fonc.2019.00512/fulldrug screeningmelanomain silicoin vitroin vivocancer |
| spellingShingle | Gabriela Klein Couto Natália Vieira Segatto Thaís Larré Oliveira Fabiana Kömmling Seixas Kyle M. Schachtschneider Kyle M. Schachtschneider Kyle M. Schachtschneider Tiago Collares The Melding of Drug Screening Platforms for Melanoma Frontiers in Oncology drug screening melanoma in silico in vitro in vivo cancer |
| title | The Melding of Drug Screening Platforms for Melanoma |
| title_full | The Melding of Drug Screening Platforms for Melanoma |
| title_fullStr | The Melding of Drug Screening Platforms for Melanoma |
| title_full_unstemmed | The Melding of Drug Screening Platforms for Melanoma |
| title_short | The Melding of Drug Screening Platforms for Melanoma |
| title_sort | melding of drug screening platforms for melanoma |
| topic | drug screening melanoma in silico in vitro in vivo cancer |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00512/full |
| work_keys_str_mv | AT gabrielakleincouto themeldingofdrugscreeningplatformsformelanoma AT nataliavieirasegatto themeldingofdrugscreeningplatformsformelanoma AT thaislarreoliveira themeldingofdrugscreeningplatformsformelanoma AT fabianakommlingseixas themeldingofdrugscreeningplatformsformelanoma AT kylemschachtschneider themeldingofdrugscreeningplatformsformelanoma AT kylemschachtschneider themeldingofdrugscreeningplatformsformelanoma AT kylemschachtschneider themeldingofdrugscreeningplatformsformelanoma AT tiagocollares themeldingofdrugscreeningplatformsformelanoma AT gabrielakleincouto meldingofdrugscreeningplatformsformelanoma AT nataliavieirasegatto meldingofdrugscreeningplatformsformelanoma AT thaislarreoliveira meldingofdrugscreeningplatformsformelanoma AT fabianakommlingseixas meldingofdrugscreeningplatformsformelanoma AT kylemschachtschneider meldingofdrugscreeningplatformsformelanoma AT kylemschachtschneider meldingofdrugscreeningplatformsformelanoma AT kylemschachtschneider meldingofdrugscreeningplatformsformelanoma AT tiagocollares meldingofdrugscreeningplatformsformelanoma |